Researchers searched Medline, Embase and Web of Science from January 1978 through December 2016 to identify studies that assessed the association between tetracycline use and risk of C. diff. They included six studies, four case control and two cohort, with patient recruitment between 1993 and 2012.
The researchers found that that tetracyclines were associated with a decreased risk of C. diff. Additionally, subgroup analysis of studies that evaluated the risk of C. diff with doxycycline alone also demonstrated a decreased risk of the infection.
“It may be reasonable to use tetracyclines whenever appropriate to decrease CDI associated with antibiotic use,” study authors concluded.
More articles on healthcare quality:
5 resources to promote national influenza vaccination week
CDC policy boosted baby boomer hep C screening rates by nearly 50%
Meningococcal disease, legionnaires’, drug-resistant TB: 5 recent and ongoing outbreaks
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
